Generate Biomedicines, Inc.
NASDAQ:GENBAsset Management
+$0.13 today
- Market cap
- $1.34B
- Beta
- 0.19
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$4.06
Volume 1.05M
Average 0.55M
GENB EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Generate Biomedicines, Inc.NASDAQ: GENB
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA of -$60.84M in Q1 FY2026
Q1 FY2026 EBITDA was -$60.84M.
Context
- EBITDA amounted to 653.7% of revenue in FY2025, down 146.5 pp from a year earlier.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of -$116.82M (+44.0%) for the fiscal year ending Dec 2026, a step up from the -27.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$60.84M— QoQ
- Last fiscal yearDec 2025
- -$208.49M-27.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | -27.4% | +44.0% | +71.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (208.49M) USD
- Year-over-year change
- -27.4%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (208.49M) | -27.4% |
| FY2024 | 2024-12-31 | (163.71M) | — |
EBITDA vs competitors
How GENB compares with its peers on the latest reported figures
- GENB's FY2025 EBITDA of -$208.49M is the lowest of the 5 companies compared; the peer median is -$111.96M.
- Its year-over-year change of -27.4% is the 4th highest of 5, against a peer median of +10.2%.
- EBITDA amounts to 653.7% of revenue for GENB, versus a peer median of 3011.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$106.12M | +42.0% | — | 106.5% | |
| LTM Mar 2026 | -$106.84M | -14.3% | — | 5818.9% | |
| LTM Mar 2026 | -$117.09M | -106.8% | — | 9007.0% | |
| LTM Sep 2026 | -$138.65M | +34.7% | — | 204.3% | |
GENBGenerate Biomedicines, Inc. | FY2025 | -$208.49M | -27.4% | — | 653.7% |
| Peer median (excluding GENB) | -$111.96M | +10.2% | — | 3011.6% | |
Competitors are the stored peer set for GENB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Revenue | 20.46M | 31.89M |
| Cost of Revenue | 0 | 0 |
| Gross Profit | 20.46M | 31.89M |
| Gross Margin | 100.0% | 100.0% |
| Research & Development | 175.31M | 224.7M |
| Selling, General & Admin | 42.09M | 42.26M |
| Operating Expenses | 217.4M | 266.96M |
| Depreciation & Amortization | 15.35M | 13.18M |
| EBITDA | (163.71M) | (208.49M) |
| EBITDA Margin | -800.2% | -653.7% |
| Operating Income | (196.94M) | (235.07M) |
| Operating Margin | -962.6% | -737.0% |
| Interest Income | 18.12M | 13.66M |
| Interest Expense | 2.12M | 1.14M |
| Other Income / Expenses | 15.77M | 12.26M |
| Income Before Tax | (181.17M) | (222.8M) |
| Pre-Tax Margin | -885.5% | -698.6% |
| Income Tax Expense | 212K | 163K |
| Net Income | (173.77M) | (203.15M) |
| Net Margin | -849.4% | -637.0% |
| EPS (Basic) | (1.68) | (4.98) |
| EPS (Diluted) | (1.68) | (4.98) |
| Weighted Avg Shares | 127.45M | 50.09M |
| Weighted Avg Shares (Diluted) | 127.45M | 50.09M |
Generate Biomedicines, Inc.
NASDAQ:GENB
Intrinsic Alpha fair value
Locked
Current Price
$10.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.